The invention relates to the expression of two molecules in viral vectors AAV/IGF2-HA and AAV/IGF2, the associated method and use thereof in the amelioration of protein misfolding-related diseases, such as Huntington's disease, as presented in the in vivo models in FIG. 11/19.